Brammer Bio investing $50M in gene-therapy facility

Gene therapy

A brand-new CDMO is pushing forward with plans to be a player in gene-based drug manufacturing with a new manufacturing facility in a U.S. biotech hub.

Lexington, MA-based Brammer Bio laid out its plans at the BIO International event in San Francisco, saying it will spend about $50 million to outfit and staff a 50,000-square-foot facility in its home city for production of late-stage and commercial-scale viral vector and cell-based therapies.

Brammer Bio expects the facility to be operating by Q2 of next year. The plan is to eventually add 200 employees to its workforce there.


[Infographic] Machine Learning, Statistics and Optimizing Outcomes

In our infographic, we outline the potential of fusing machine learning and statistics algorithms together to more efficiently analyze clinical trial data output and ultimately revolutionize clinical research.

Brammer Bio was formed in March through the merger of Brammer Biopharmaceuticals and Alachua, FL-based Florida Biologix, with the help of a capital infusion from Ampersand Capital Partners, Florida Biologix's majority owner.

"The Lexington facility will be equipped for largescale manufacturing with a focus on compliance in these emerging drug categories,” Richard Snyder, Brammer CSO, said in a statement.

The company also has 45,000 square feet of process development and Phase I/II clinical manufacturing space in Alachua, FL, and intends to double that.

As more and more of the specialty drugs being developed by biotech and pharma are gene-based therapies, Brammer joins Japan’s Fujifilm Diosynth Biotechnologies and others like Swiss CDMO Lonza, in hustling to build or expand facilities to manufacture them.

- read the announcement 

Related Articles: 
New player jumping into cell therapies manufacturing 
Merck to outfit $60M biologics plant for Fujifilm to use

Suggested Articles

Novartis' AveXis will use Catalent for some manufacturing of its newly approved gene therapy Zolgensma and more manufacturing news of note.

Pharmacy chain Rite Aid has partnered with Google to have their drug recycling stations easily searchable on Google Maps. 

Precision BioSciences says it will have a manufacturing facility for its off-the-shelf CAR-T therapies up and running in the fourth quarter.